Exact Sciences Corp., of Madison, Wis., just unveiled three studies of the Oncotype Dx Breast Recurrence Score test during the virtual 2020 American Society of Clinical Oncology Annual Meeting. According to the company, the findings highlight the value of the test for personalizing and improving neoadjuvant treatment decisions in women with hormone receptor positive, HER2-negative breast cancer. Emilio Alba, director of the medical oncology units at the Hospital Universitario Virgen de la Victoria in Malaga, Spain, said these results hold special importance, given that screening and diagnostic oncology services are being delayed in the wake of COVID-19. "This new evidence shows that the Oncotype Dx test may be used to inform neoadjuvant therapy while awaiting surgery, therefore helping us to overcome some of the unique challenges we are currently facing in managing breast cancer patients,” he added.

Earlier TAVR may be better for asymptomatic stenosis in presence of left ventricular hypertrophy

Medical science continues to define the relative risks of progressively smaller patient subsets across the disease spectrum, but this is particularly true of late in connection with aortic stenosis. A new article in a medical journal makes the case that the presence of left ventricular hypertrophy should not dissuade the clinician from recommending transcatheter aortic valve replacement for asymptomatic aortic stenosis because for some of these patients, outcomes actually improve with earlier TAVR implant.

Memed secures CE mark for new POC blood test

LONDON – After eight years in development, Memed Ltd. has secured CE marking for its point of care blood test, which is able to distinguish between bacterial and viral infections in 15 minutes. The approval opens the way for commercial roll out of the Memed-BV diagnostic and for the underlying technology Memed Key to form the basis of further blood biomarker diagnostics, to be developed in house and by licensing partners.

Launchpad nabs $1.8M grant for pivotal animal study of dental bone graft solution

Lowell, Mass.-based startup Launchpad Medical LLC said Tuesday that it has picked up an additional $1.8 million in grant money from the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center to advance the development of its Tetranite-based bone graft solution. The company plans to use the funds to conduct a pivotal animal study of the technology and generate the necessary data to support an IDE submission to the U.S. FDA to initiate a clinical trial.

Toronto joins Texas in $7.44M project to cut down on repeat cancer surgeries

TORONTO – Seven years after setting up shop in downtown Toronto, high res, surgical imaging medtech Perimeter Imaging Inc. (PMI) is still wrestling with a statistical heartbreaker: 1 in 4 patients told to return for a second surgery to remove cancerous breast tissue after the first surgery failed to get it all. Now PMI has said it can cut that number down dramatically thanks to a $7.44 million investment from the Austin, Texas-based Cancer Prevention and Research Institute of Texas (CPRIT) to identify wayward breast cancer cells using artificial intelligence technology. “What we are trying to do is to provide some of the information the pathology lab normally takes days to supply days while the patient is still on the table,” PMI co-founder and program grant director Andrew Berkeley told BioWorld. “

Free access to BioWorld coronavirus articles

The articles from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak are available at www.bioworld.com/coronavirus. Note that we have added three critical tables which are constantly updated:

Also in the news

Avita Medical, Aytu Bioscience, Biomodex, Biosensors, Citius, Fibralign, Gelesis, Icometrix, Know Labs, Lumendi, Medx, Mybio, Myndtec, Nuprobe, Orasure Technologies, Ourcrowd, Polarean Imaging, Protech Home Medical, Qualigen Therapeutics, Respira Technologies, Re-vana Therapeutics, Royal Philips, Steeper Group, Surgery Exchange, Technopath Clinical Diagnostics, Terumo, Varian, Zoll Medical

No Comments